New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
07:14 EDTOGXIOncoGenex's Synergy did not meet primary endpoint in Phase 3 trial
OncoGenex Pharmaceuticals announced results from the Phase 3 SYNERGY trial. Top-line survival results indicate that the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival in men with metastatic castrate-resistant prostate cancer, or CRPC, compared to docetaxel/prednisone alone. The adverse events observed were similar to custirsen's known adverse event profile.
News For OGXI From The Last 14 Days
Check below for free stories on OGXI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 7, 2014
16:09 EDTOGXIOncoGenex reports Q2 EPS (47c), consensus (55c)
Reports Q2 revenue $4.9M, may not compare to consensus $9.92M.
09:08 EDTOGXIOn The Fly: Pre-market Movers
Subscribe for More Information
06:51 EDTOGXIOncoGenex appoints John A. Bencich as CFO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use